Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
종목 코드 SCLX
회사 이름Scilex Holding Co
상장일Jan 11, 2021
CEOJi (Henry H)
직원 수115
유형Ordinary Share
회계 연도 종료Jan 11
주소960 San Antonio Road
도시PALO ALTO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94303
전화16505164310
웹사이트https://www.scilexholding.com/
종목 코드 SCLX
상장일Jan 11, 2021
CEOJi (Henry H)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음